Science & Enterprise subscription

Follow us on Twitter

  • Four pharmaceutical companies are signing on to an initiative that promises to make clinical trials friendlier to p… https://t.co/VNbOdOc8i5
    about 6 hours ago
  • New post on Science and Enterprise: Pharmas Join Digital Clinical Trial Project https://t.co/FkhSAEntxd #Science #Business
    about 6 hours ago
  • A robot device is being developed that can fly through the air and drive along the ground with a single motor, and… https://t.co/hyeUKY5hR0
    about 10 hours ago
  • New post on Science and Enterprise: Flying, Driving Drone Robot Unveiled https://t.co/5aAqW1FhfK #Science #Business
    about 10 hours ago
  • A new enterprise in the U.K. is creating treatments with stem cells to repair damaged nerve cells in the inner ear… https://t.co/y4qOmPcuWK
    about 1 day ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

In Case You Missed It …

(tigerlily713, Pixabay)

5 August 2018. If you want a preview of the impact artificial intelligence can make on our life and work, read our story this past week about a project at University of North Carolina in Chapel Hill. A bioinformatics team at the school’s pharmacy school developed a system combining machine learning and neural networks with large-scale databases to design entirely new drug molecules that meet targeted chemical properties and biological activity.

In this case, the system known as Reinforcement Learning for Structural Evolution or Release, uses reinforcement learning in a two-stage process to design drug molecules from scratch. The system seeks to harness the power of artificial intelligence to speed the design of new and more complex therapies. As a proof-of-concept, the UNC team applied the Release system to design inhibitors of a protein called Janus kinase 2, or JAK2, from a gene that codes for stimulating growth and proliferation of cells.

Here are other stories we covered last week:

*     *     *

 

Please share Science & Enterprise ...
error

Comments are closed.